Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piramal Looks To Build On Pharma Growth

Q2 Results Show 17% Increase In Global Pharma Business

Executive Summary

Piramal says it is looking to build on the 17% growth in its Global Pharma business reported in its financial second quarter by investing in manufacturing expansion across differentiated product areas.

You may also be interested in...



Manufacturing Round-Up: FDA Demands Meeting With Aurobindo Over Issues At Multiple Sites

An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.

Kelix Strikes A Deal To Acquire 14 Oncology Injectables

Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.

Cipla And mAbxience Partner For Essential Biosimilars In South Africa

Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel